Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Lobe Sciences (LOBE) has signed an agreement with iNGENu Pty Ltd.
  • iNGENu is a Contract Research Organization (CRO) based out of Australia that will design and conduct three or more clinical trials to evaluate Lobe’s proprietary psilocin analogues
  • Lobe Sciences (LOBE) is a life sciences company focused on psychedelic medicines
  • Lobe Sciences (LOBE) is trading steady at C$0.06 per share at 9:40 am ET

Lobe Sciences Ltd. (LOBE) has signed an agreement with iNGENu Pty Ltd.

iNGENu is a Contract Research Organization (CRO) based out of Australia that will design and conduct three or more clinical trials to evaluate Lobe’s proprietary psilocin analogues L-130 or L-131.

Lobe Sciences’ CEO, Philip Young stated that this partnership comes at a time when his company is moving its proprietary stable psilocin products into human clinical trials.

“iNGENu is an industry leading, full service CRO providing end-to-end services for companies developing cannabinoid and psychedelic drugs. We evaluated CRO’s in multiple geographies and chose iNGENu as their core values match ours and our commitment to discovering transformational therapies for multiple Central Nervous System diseases and trauma.”

Lobe delivers a patient friendly treatment plan that focuses on offering therapeutics in patients’ homes, physician’s offices or in the emergency department in a local hospital setting. Delivering a non-hallucinatory dose of proprietary compounds, over several days should enable patients and their personal doctors the opportunity to maintain their normal routine while receiving treatment, allowing significantly more people access to this new therapeutic approach.

Lobe Sciences Ltd. (LOBE) is a life sciences company focused on psychedelic medicines.

Lobe Sciences (LOBE) is trading steady at C$0.06 per share at 9:35 am ET.


More From The Market Herald
VitalHub

" VitalHub (TSX:VHI) announces multi year contract with NHS Mid and South Essex ICB

VitalHub (VHI) announced a multi-year licensing contract with NHS Mid and South Essex Integrated Care Board (Essex).
Resverlogix Corp. - SVP of Clinical Development, Dr. Michael Sweeney.

" Resverlogix (TSX:RVX) focuses drug development on COVID-19

Clinical development of Resverlogix’s (RVX) candidate apabetalone will remain focused on preventing and treating post-COVID-19 conditions.

" No pain, no blood: BETTER Type 2 diabetes testing is coming to market

Over the past two years, reporting on the Covid-19 pandemic has dominated media airwaves.
The Market Herald Video

" BioVaxys (CSE:BIOV) expands vaccines intellectual property portfolio

BioVaxys Technology Corp. (BIOV) has broadened patent coverage for its viral vaccine platform.